Recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Conditions Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC — Anchorage, Alaska, United States View all 582 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery NCT02178241 Conditions Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +20 more Locations City of Hope Comprehensive Cancer Center — Duarte, California, United States Los Angeles County-USC Medical Center — Los Angeles, California, United States USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States Keck Medical Center of USC Pasadena — Pasadena, California, United States View all 18 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma NCT04940299 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +72 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
